Sub-Total: $0.00
INDIGO Biosciences and Bertin Pharma Sign European Distribution Agreement
Ready-to-Use Nuclear Receptor Assay kits for over 20 disease states, including Cardiovascular and Metabolic Disease, Cancer, and Inflammation
State College, PA (November 15, 2016)
INDIGO Biosciences, the recognized industry-leader in Nuclear Receptor research, and Bertin Pharma have announced the completion of a European distribution agreement. Over 40 product references for studying nuclear receptors are now available for European researchers doing their work in drug discovery and toxicology. These innovative tools are used for profiling compounds in research areas such as metabolic disorders, cardiovascular disease, cancer, obesity, and even endocrinology. These all-inclusive, cell-based, and robust kits reduce time, cost, and risk in the drug discovery process by producing easy-to-analyze, accurate results in a fraction of the time of most other kits available.
Bertin Pharma is one of the major European players for the supply of reagents and assay kits dedicated to research and development for the pharmaceutical, cosmetic, and food industries. Bertin Pharma has marketed biological reagent ranges for over 25 years. Its long R&D experience combined with its international distributor channels enable Bertin Pharma to deliver life sciences tools on time and to support customers throughout their experimentation.
With the addition of INDIGO’s portfolio of Nuclear Receptor Assay kits, Bertin Pharma completes it existing ranges of biomarker assays applied to expertise areas including metabolic syndrome, hypertension, and oncology.
“It has been a real honor to be introduced to Fred and his company, and we rapidly found a lot of complementary aspects of our businesses. The Nuclear Receptor Assay range perfectly fit with our customers’ needs, and will empower our commercial activity.” Patrick Vitaux, Bioreagent Department Manager, Bertin Pharma
“We are pleased to have reached an agreement with Bertin Pharma to expand our distribution network in Europe. We look forward to working with Patrick and his team to bring INDIGO’s assay portfolio to their customers throughout the region.” Fred Marroni, CEO, INDIGO Biosciences
About INDIGO Biosciences, Inc.
INDIGO Biosciences has established itself as an industry-leading provider of both products and services focused on nuclear receptors. INDIGO offers both screening services and assay kits for the pharmaceutical, biotechnology, agri-business, nutriceutical industries, as well as government research agencies and academic researchers.
